CIRM provides funding across five key areas: Infrastructure, Education, Discovery Research, Translational Research, and Clinical Research. By supporting projects at every stage of development, from initial discovery to clinical trials, CIRM drives progress in regenerative medicine and accelerates innovative therapies to patients.
Check out our portfolio of awards below.
All CIRM Grants
Search Filters »
| Institution |
Researcher name |
Grant Type |
Grant Title |
Award Value |
| Gladstone Institutes, J. David |
Dr. Todd C. McDevitt |
Research Leadership |
Engineering microscale tissue constructs from human pluripotent stem cells |
$5,849,100 |
| University of California, Los Angeles |
Dr. John P Chute |
Research Leadership |
Niche-Focused Research: Discovery & Development of Hematopoietic Regenerative Factors |
$4,645,297 |
| University of California, Berkeley |
Dr. Xavier Darzacq |
Research Leadership |
Single Molecule Biophysics and Biology of Cellular Identity |
$4,175,924 |
| University of California, San Francisco |
Redacted |
Research Leadership |
Recapitulating development of the musculoskeletal axis in vitro with pluripotent cells |
$0 |
| University of California, San Diego |
Dr. Eric T. Ahrens |
Research Leadership |
Molecular Imaging for Stem Cell Science and Clinical Application |
$5,680,474 |
| University of California, Santa Cruz |
Professor Richard Gregory |
Research Leadership |
MicroRNA Regulation in Stem Cells, Development, and Disease |
$0 |
| Stanford University |
Professor Hiromitsu Nakauchi |
Research Leadership |
Generation of functional cells and organs from iPSCs |
$5,426,135 |
| Gladstone Institutes, J. David |
Dr. Kevin Kit Parker PhD |
Research Leadership |
Engineering Cardiac Tissue for Regeneration and Drug Development |
$0 |
| Cedars-Sinai Medical Center |
Dr. Barry R Stripp |
Research Leadership |
Epithelial progenitors and the stromal niche as therapeutic targets in lung disease |
$4,841,830 |
| Parkinson’s Institute |
Dennis Steindler |
Research Leadership |
Stem Cell Pathologies in Parkinson’s disease as a key to Regenerative Strategies |
$0 |
| University of Southern California |
Dr. Andrew McMahon |
Research Leadership |
Repair and regeneration of the nephron |
$5,672,206 |
| University of California, Berkeley |
Dr. Zhigang He |
Research Leadership |
Developing a regeneration-based functional restoration treatment for spinal cord injury |
$0 |
| University of California, Santa Barbara |
Professor Peter J Coffey |
Research Leadership |
Development of Cellular Therapies for Retinal Disease |
$4,690,963 |
| Sanford Burnham Prebys Medical Discovery Institute |
Dr. Robert J Wechsler-Reya |
Research Leadership |
The role of neural stem cells in cerebellar development, regeneration and tumorigenesis |
$5,226,049 |
| Mohammad Pashmforoush |
Dr. Mohammad Pashmforoush |
New Faculty I |
Medical School Loan Repayment Program |
$27,949 |
| Salk Institute for Biological Studies |
Dr. Dana Leanne Jones |
New Faculty I |
Characterization of mechanisms regulating de-differentiation and the re-acquisition of stem cell identity |
$2,134,100 |
| University of California, Los Angeles |
Dr. Dana Leanne Jones |
New Faculty I |
Characterization of mechanisms regulating de-differentiation and the re-acquisition of stem cell identity |
$382,773 |
| University of California, Los Angeles |
Dr. Siavash Kurdistani |
New Faculty I |
Epigenetics in cancer stem cell initiation and clinical outcome prediction |
$3,063,450 |
| University of California, Santa Cruz |
Dr. Camilla Forsberg |
New Faculty I |
Mechanisms of Stem Cell Fate Decisions |
$2,201,759 |
| University of Southern California |
Dr. Mohammad Pashmforoush |
New Faculty I |
Transcriptional Regulation of Cardiac Pacemaker Cell Progenitors |
$2,816,578 |
| University of California, Berkeley |
Dr. Irina M. Conboy |
New Faculty I |
Identification of hESC-mediated molecular mechanism that positively regulates the regenerative capacity of post-natal tissues |
$2,246,020 |
| University of California, Santa Cruz |
Dr. Bin Chen |
New Faculty I |
Molecular mechanisms of neural stem cell differentiation in the developing brain |
$2,147,592 |
| University of California, Los Angeles |
Dr. Kathrin Plath Dr. |
New Faculty I |
In vitro reprogramming of mouse and human somatic cells to an embryonic state |
$2,229,427 |
| The Regents of the University of California on behalf of its Riverside Campus |
Dr. Douglas Ethell |
New Faculty I |
ES-Derived Cells for the Treatment of Alzheimer’s Disease |
$621,639 |
| Western University of Health Sciences |
Dr. Douglas W Ethell |
New Faculty I |
ES-Derived Cells for the Treatment of Alzheimer’s Disease |
$1,401,642 |
| University of California, Davis |
Dr. Chong-Xian Pan |
New Faculty I |
Combinatorial Chemistry Approaches to Develop LIgands against Leukemia Stem Cells |
$2,386,409 |
| University of California, Los Angeles |
Dr. Hanna Mikkola |
New Faculty I |
Mechanisms of Hematopoietic stem cell Specification and Self-Renewal |
$2,286,900 |
| City of Hope, Beckman Research Institute |
Dr. Tiziano Barberi |
New Faculty I |
Skeletal muscle development from hESC and its in vivo applications in animal models of muscular dystrophy |
$131,840 |
| Scripps Research Institute |
Dr. Kristin K Baldwin Dr. |
New Faculty I |
Generating pluripotent cell lines from neurons. |
$2,786,560 |
| Salk Institute for Biological Studies |
Dr. Lei Wang |
New Faculty I |
Genetic Encoding Novel Amino Acids in Embryonic Stem Cells for Molecular Understanding of Differentiation to Dopamine Neurons |
$2,587,742 |
| Stanford University |
Dr. Anne Brunet |
New Faculty I |
Molecular mechanisms involved in adult neural stem cell maintenance |
$2,348,435 |
| University of California, Merced |
Dr Jennifer O Manilay |
New Faculty I |
Enhancing Survival of Embryonic Stem Cell-Derived Grafts by Induction of Immunological Tolerance |
$1,576,389 |
| University of California, Irvine |
Dr. Andrew Putnam |
New Faculty I |
A Novel Engineered Niche to Explore the Vasculogenic Potential of Embryonic Stem Cells |
$395,764 |
| Stanford University |
Dr. Joanna Wysocka PhD |
New Faculty I |
Trithorax and Polycomb methyltransferase complexes in cell fate determination. |
$2,373,903 |
| University of California, San Diego |
Dr. David Traver |
New Faculty I |
Genetic dissection of mesodermal commitment to the hematopoietic fates. |
$2,150,620 |
| University of Southern California |
Dr. Songtao Shi |
New Faculty I |
Oral and Craniofacial Reconstruction Using Mesenchymal Stem Cells |
$3,242,651 |
| Scripps Research Institute |
Dr. Sheng Ding Dr. |
New Faculty I |
Reprogramming of human somatic cells back to pluripotent embryonic stem cells |
$1,393,876 |
| Gladstone Institutes, J. David |
Sheng Ding PhD |
New Faculty I |
Reprogramming of human somatic cells back to pluripotent embryonic stem cells |
$1,320,101 |
| Stanford University |
Karl Deisseroth |
New Faculty I |
Bioengineering technology for fast optical control of differentiation and function in stem cells and stem cell progeny |
$2,424,209 |
| Stanford University |
Dr. Howard Y. Chang |
New Faculty I |
Noncoding RNAs in Cell Fate Determination |
$2,985,894 |
| BioTime, Inc. |
Dr. Michael D West Ph.D. |
Early Translational I |
Addressing the Cell Purity and Identity Bottleneck Through Generation and Expansion of Clonal Human Embryonic Progenitor Cell Lines |
$4,721,706 |
| University of California, Davis |
Dr. Alice F Tarantal |
Early Translational I |
In Utero Model to Assess the Fate of Transplanted Human Cells for Translational Research and Pediatric Therapies |
$3,143,392 |
| Salk Institute for Biological Studies |
Dr. Inder M. Verma |
Early Translational I |
Curing Hematological Diseases |
$5,979,252 |
| Sanford Burnham Prebys Medical Discovery Institute |
Dr Evan Y Snyder |
Early Translational I |
Developmental Candidates for Cell-Based Therapies for Parkinson’s Disease (PD) |
$5,190,752 |
| Stanford University |
Dr. Jill Helms |
Early Translational I |
Enhancing healing via Wnt-protein mediated activation of endogenous stem cells |
$6,464,126 |
| Jackson Labs |
Pali G. Kaur |
Early Translational I |
Mouse Models for Stem Cell Therapeutic Development |
$3,759,134 |
| Gladstone Institutes, J. David |
Dr. Warner C Greene |
Early Translational I |
Maximizing the Safety of Induced Pluripotent Stem Cells as an Infusion Therapy: Limiting the Mutagenic Threat of Retroelement Retrotransposition during iPSC Generation, Expansion and Differentiation |
$1,280,001 |
| Scripps Research Institute |
Dr. Martin Friedlander |
Early Translational I |
Autologous Retinal Pigmented Epithelial Cells Derived from Induced Pluripotent Stem Cells for the Treatment of Atrophic Age Related Macular Degeneration |
$5,806,321 |
| University of California, Los Angeles |
Dr. Gabriel H. Travis |
Early Translational I |
Development of a Stem Cell-based Transplantation Strategy for Treating Age-related Macular Degeneration |
$5,487,136 |
| Scripps Research Institute |
Dr. Jeanne F Loring |
Early Translational I |
Ensuring the safety of cell therapy: a quality control pipeline for cell purification and validation |
$5,830,771 |
